



Bayer-THU Collaboration

Call for Application

2025 Bayer Investigator Award

Collaborate to Cure Hub China
Bayer Pharmaceuticals

拜耳处方药中国合作创新中心

Dec 2025



RESTRICTED



Introduction

About Bayer Investigator Award

Bayer Investigator Award is presented annually to Tsinghua University Investigators in recognition of their scientific excellence in the research field relevant to Bayer Pharma R&D. Selected Bayer Investigators will get the following supports:

- // CNY 150,000 award for each selected Bayer Investigator
- // Get connected to Bayer scientists for potential research collaboration discussion

Who May Apply?


Eligibility criteria of the Bayer Investigators are:

- // Full-time employees of THU at the time of applying and receiving the award
- // Working in the School of Life Sciences, Tsinghua Medicine, or Department of Chemistry of Tsinghua
- // Independent of having a project with Bayer or not
- // **Must not** be healthcare professionals, or employed by a hospital due to international compliance requirements
- // Members of the Joint Steering Committee (JSC) may not apply for the award
- // Have not been selected as Bayer Investigator in the previous 36 months



Selection


Considerations

 Research excellence, e.g. publication records over the past five years (2020 – 2025)

 Research relevance to **Bayer's areas of interest**



Decision

 Selection will be conducted by the Joint Steering Committee (JSC) from both Bayer and Tsinghua University

- // **New targets, increased disease understanding, biomarkers, access to clinical resources**
- // **Precision Oncology** (i.e. precision drug development (PDD) approach)
 - // PDD refers to having a deep understanding of the target to disease link in defined patient populations, where modulating target biology with a fit for purpose modality will create measurable impact
 - // Tumor types in focus: GI (CRC, HCC, gastric), GU (prostate, bladder, RCC), lung cancer
- // **Precision cardiorenal diseases** (e.g. Heart Failure, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease)
- // **Neurology & Rare diseases** enabled by cell and gene therapy
- // **Immunology & Inflammation** (e.g. SLE, IBD)
- // **Radiology** Molecular imaging tracers
- // **Novel technologies / platforms** that enable target identification/entry into druggability, specifically:
 - // Interactome analysis, methods for identification of new allosteric pockets and binders, multi-omics techniques, structural biology and biophysical methods (e.g. X-Ray, cryo-EM, AS MS, NMR, etc.), bioinformatics
 - // Acceleration of learning cycles: Organ on chip to accelerate insights generation for new targets and cps, prediction/ data science aspects specifically for acceleration of learning cycles, ML & AI
 - // Formulation technologies, targeted drug delivery: e.g. organ specific LNPs, etc.
 - // Screening technologies, HTS, DEL, imaging technologies, phenotypic screens
 - // Automated chemistry, direct to biology (D2B) approaches
- // **Therapeutic modalities** ("Creating molecules that matter")
 - // Small molecules and non-traditional SMOLs (such as covalent binders, molecular glues, protein degraders, RNA binders, fragments, bRo5), peptides, therapeutic antibodies, targeted radiotherapeutics, conjugated modalities in general (antibody, peptide, glyco, radio), antisense and siRNA therapeutics



Application Process

1 Fill out the Application Form, which includes:

- // A short description of research interests and achievements
- // A list of relevant publications, and publications aligned with Bayer's areas of interest (if any)
- // Curriculum Vitae

2 Submit your application to Bayer and THU Alliance Managers:

Duan Wang (王端)

Collaborate to Cure Hub China
Bayer Pharmaceuticals

Mobile: +86 18221448381
E-mail: duan.wang@bayer.com

Yuxin Li (李玉鑫)

Biomedical Innovation Office
Tsinghua University

Tel: +86 10 6278 1816
Mobile: +86 13848615270
E-mail: yuxin-li@mail.tsinghua.edu.cn

3 Application deadline is **Jan 30th, 2026**.

4 Decision letters will be sent out in March 2026

Health for all, Hunger for none



Thank
you!

bayer.com